{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T10:39:07Z","timestamp":1791542347632,"version":"4.3.4"},"reference-count":106,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.eururo.2025.06.013","type":"journal-article","created":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T19:30:48Z","timestamp":1752953448000},"page":"437-448","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Novel Therapeutic Strategies for Metastatic Prostate Cancer Care"],"prefix":"10.1016","volume":"88","author":[{"given":"Alessia","family":"Cimadamore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Boixareu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Sharp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himisha","family":"Beltran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2034-595X","authenticated-orcid":false,"given":"Johann S.","family":"de Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2025.06.013_b0005","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.eururo.2025.06.013_b0010","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.eururo.2018.03.028","article-title":"Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology","volume":"75","author":"Nuhn","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.06.013_b0015","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1038\/onc.2013.206","article-title":"Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches","volume":"32","author":"Karantanos","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.eururo.2025.06.013_b0020","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/j.1742-1241.2011.02799.x","article-title":"Characterising the castration-resistant prostate cancer population: a systematic review","volume":"65","author":"Kirby","year":"2011","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.eururo.2025.06.013_b0025","unstructured":"U.S. Food and Drug Administration. FDA approves olaparib for HRR gene-mutated metastatic castration-resistant prostate cancer. Silver Spring, MD: U.S. Food and Drug Administration; 2020. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer."},{"key":"10.1016\/j.eururo.2025.06.013_b0030","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1016\/S1470-2045(19)30688-6","article-title":"Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial","volume":"20","author":"Khalaf","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.06.013_b0035","unstructured":"Oncternal Therapeutics. Oncternal Therapeutics announces termination of its clinical programs. San Diego, CA: Oncternal Therapeutics; 2023. https:\/\/investor.oncternal.com\/news-releases\/news-release-details\/oncternal-therapeutics-announces-termination-its-clinical\/."},{"key":"10.1016\/j.eururo.2025.06.013_b0040","doi-asserted-by":"crossref","first-page":"6377","DOI":"10.1038\/s41598-021-85969-x","article-title":"Phase Ib trial of reformulated niclosamide with abiraterone\/prednisone in men with castration-resistant prostate cancer","volume":"11","author":"Parikh","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.eururo.2025.06.013_b0045","doi-asserted-by":"crossref","first-page":"5031","DOI":"10.1200\/JCO.2021.39.15_suppl.5031","volume":"39","author":"de Bono","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.06.013_b0050","doi-asserted-by":"crossref","first-page":"S990","DOI":"10.1016\/j.annonc.2024.08.1722","article-title":"1641P Phase I\/II trial of oral masofaniten (EPI-7386) in combination with enzalutamide (Enz) compared to Enz alone in metastatic castration-resistant prostate cancer (mCRPC) subjects","volume":"35","author":"Kyriakopoulos","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2025.06.013_b0055","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.eururo.2019.08.034","article-title":"Androgen receptor modulation optimized for response-splice variant: a phase 3, randomized trial of galeterone versus enzalutamide in androgen receptor splice variant-7-expressing metastatic castration-resistant prostate cancer","volume":"76","author":"Taplin","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.06.013_b0060","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1200\/JCO.2022.40.6_suppl.017","article-title":"Phase 1\/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC)","volume":"40","author":"Gao","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.06.013_b0065","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.annonc.2024.09.005","article-title":"Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer","volume":"36","author":"Rathkopf","year":"2025","journal-title":"Ann Oncol"},{"issue":"suppl_2","key":"10.1016\/j.eururo.2025.06.013_b0070","first-page":"S962","article-title":"Clinical activity of BMS-986365 (CC-94676), a dual androgen receptor (AR) ligand-directed degrader and antagonist, in heavily pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","volume":"35","author":"Patel","year":"2024","journal-title":"Ann Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.eururo.2025.06.013_b0075","doi-asserted-by":"crossref","first-page":"S968","DOI":"10.1016\/j.annonc.2024.08.1686","article-title":"Opevesostat (MK-5684\/ODM-208), an oral CYP11A1 inhibitor, in metastatic castration-resistant prostate cancer (mCRPC): Updated CYPIDES phase II results","volume":"35","author":"Fizazi","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2025.06.013_b0080","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1158\/1535-7163.MCT-22-0115","article-title":"First-in-class small molecule to inhibit CYP11A1 and steroid hormone biosynthesis","volume":"21","author":"Karimaa","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.eururo.2025.06.013_b0085","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/76287","article-title":"Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor","volume":"6","author":"Zhao","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.eururo.2025.06.013_b0090","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.972572","article-title":"Glucocorticoid receptor and androgen receptor-targeting therapy in patients with castration-resistant prostate cancer","volume":"12","author":"Pak","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.eururo.2025.06.013_b0095","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1158\/1078-0432.CCR-21-1090","article-title":"The effect of corticosteroids on prostate cancer outcome following treatment with enzalutamide: a multivariate analysis of the phase III AFFIRM trial","volume":"28","author":"Zhao","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"16_suppl","key":"10.1016\/j.eururo.2025.06.013_b0100","doi-asserted-by":"crossref","first-page":"5062","DOI":"10.1200\/JCO.2023.41.16_suppl.5062","article-title":"Phase I trial of enzalutamide (Enz) plus the glucocorticoid receptor antagonist relacorilant (Rela) for patients with metastatic castration-resistant prostate cancer","volume":"41","author":"Desai","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.06.013_b0105","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1158\/1078-0432.CCR-21-4049","article-title":"Phase I\/II trial of enzalutamide and mifepristone, a glucocorticoid receptor antagonist, for metastatic castration-resistant prostate cancer","volume":"28","author":"Serritella","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2025.06.013_b0110","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1158\/1078-0432.CCR-23-3508","article-title":"Phase I study of ORIC-101, a glucocorticoid receptor antagonist, in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer progressing on enzalutamide","volume":"30","author":"Abida","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2025.06.013_b0115","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1126\/science.abf8403","article-title":"Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis","volume":"374","author":"Pernigoni","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.eururo.2025.06.013_b0120","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.ccell.2019.10.005","article-title":"Cistrome partitioning reveals convergence of somatic mutations and risk variants on master transcription regulators in primary prostate tumors","volume":"36","author":"Mazrooei","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eururo.2025.06.013_b0125","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/s41588-020-0664-8","article-title":"Prostate cancer reactivates developmental epigenomic programs during metastatic progression","volume":"52","author":"Pomerantz","year":"2020","journal-title":"Nat Genet"},{"key":"10.1016\/j.eururo.2025.06.013_b0130","doi-asserted-by":"crossref","first-page":"4900","DOI":"10.1038\/s41467-018-07270-2","article-title":"Integrative epigenetic taxonomy of primary prostate cancer","volume":"9","author":"Stelloo","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.eururo.2025.06.013_b0135","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1038\/s41388-024-03148-4","article-title":"AR coactivators, CBP\/p300, are critical mediators of DNA repair in prostate cancer","volume":"43","author":"Sardar","year":"2024","journal-title":"Oncogene"},{"issue":"suppl_7","key":"10.1016\/j.eururo.2025.06.013_b0140","first-page":"S616","article-title":"A phase II study of ZEN-3694 (ZEN), enzalutamide (ENZ), and pembrolizumab (P) in metastatic castration-resistant prostate cancer (mCRPC): Interim safety results","volume":"33","author":"Jindal","year":"2022","journal-title":"Ann Oncol"},{"issue":"15_suppl","key":"10.1016\/j.eururo.2025.06.013_b0145","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1200\/JCO.2020.38.15_suppl.3618","article-title":"BET inhibitor molibresib for the treatment of advanced solid tumors: final results from an open-label phase I\/II study","volume":"38","author":"Cousin","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.06.013_b0150","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1200\/JCO.2018.78.2292","article-title":"Phase Ib trial with birabresib, a small-molecule inhibitor of bromodomain and extraterminal proteins, in patients with selected advanced solid tumors","volume":"36","author":"Lewin","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.06.013_b0155","doi-asserted-by":"crossref","first-page":"5338","DOI":"10.1158\/1078-0432.CCR-20-1707","article-title":"A phase Ib\/IIa study of the pan-BET inhibitor ZEN-3694 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer","volume":"26","author":"Aggarwal","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"15_suppl","key":"10.1016\/j.eururo.2025.06.013_b0160","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS5089","article-title":"An open label phase I\/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy and in combination in patients with advanced solid\/metastatic tumors","volume":"37","author":"de Bono","year":"2019","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"10.1016\/j.eururo.2025.06.013_b0165","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1200\/JCO.2023.41.6_suppl.184","article-title":"An oral androgen receptor RIPTAC for prostate cancer","volume":"41","author":"Raina","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.06.013_b0170","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.3390\/ijms24032046","article-title":"AR and PI3K\/AKT in prostate cancer: a tale of two interconnected pathways","volume":"24","author":"Tortorella","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.eururo.2025.06.013_b0175","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.eururo.2014.10.027","article-title":"PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate","volume":"67","author":"Ferraldeschi","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.06.013_b0180","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.eururo.2024.12.015","article-title":"Final overall survival and molecular data associated with clinical outcomes in patients receiving ipatasertib and abiraterone in the phase 3 IPATential150 trial","volume":"87","author":"de Bono","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.06.013_b0185","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(21)00580-8","article-title":"Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial","volume":"398","author":"Sweeney","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2025.06.013_b0190","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1158\/1078-0432.CCR-18-0981","article-title":"Randomized phase II study evaluating Akt blockade with ipatasertib, in combination with abiraterone, in patients with metastatic prostate cancer with and without PTEN loss","volume":"25","author":"de Bono","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2025.06.013_b0195","unstructured":"Ryan C. Phase 3 study of capivasertib plus chemo\/ADT in mCRPC to end after recommendation from data monitoring committee. OncLive. 2025 May 1. https:\/\/www.onclive.com\/view\/phase-3-study-of-capivasertib-plus-chemo-adt-in-mcrpc-to-end-after-recommendation-from-data-monitoring-committee."},{"key":"10.1016\/j.eururo.2025.06.013_b0200","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in hormone receptor-positive advanced breast cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.06.013_b0205","unstructured":"AstraZeneca. Truqap combination in PTEN-deficient metastatic hormone-sensitive prostate cancer demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 phase III trial. AstraZeneca; 2024 Nov 25. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2024\/truqap-improved-rpfs-in-advanced-prostate-cancer.html."},{"issue":"Suppl 6","key":"10.1016\/j.eururo.2025.06.013_b0210","article-title":"Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer","volume":"9","author":"Jim\u00e9nez-Vacas","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.eururo.2025.06.013_b0215","doi-asserted-by":"crossref","first-page":"5873","DOI":"10.1038\/s41467-024-50262-8","article-title":"Loss of tumor suppressors promotes inflammatory tumor microenvironment and enhances LAG3+T cell mediated immune suppression","volume":"15","author":"Zahraeifard","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.eururo.2025.06.013_b0530","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","article-title":"Overall survival with palbociclib and fulvestrant in advanced breast cancer","volume":"379","author":"Turner","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.06.013_b0220","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.trecan.2019.03.005","article-title":"Cell Cycle and Beyond: Exploiting New RB1 Controlled Mechanisms for Cancer Therapy","volume":"5","author":"Knudsen","year":"2019","journal-title":"Trends Cancer."},{"issue":"8_Suppl","key":"10.1016\/j.eururo.2025.06.013_b0225","article-title":"CYCLONE 1: Abemaciclib in men with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC)","volume":"83","author":"Agarwal","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2025.06.013_b0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107669","article-title":"Combined TP53 and RB1 loss promotes prostate cancer resistance to a spectrum of therapeutics and confers vulnerability to replication stress","volume":"31","author":"Nyquist","year":"2020","journal-title":"Cell Rep"},{"key":"10.1016\/j.eururo.2025.06.013_b0235","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adf6732","article-title":"Targeting DNA methylation and B7-H3 in RB1-deficient and neuroendocrine prostate cancer","volume":"15","author":"Yamada","year":"2023","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.eururo.2025.06.013_b0240","doi-asserted-by":"crossref","first-page":"6779","DOI":"10.1038\/s41467-024-51156-5","article-title":"Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes","volume":"15","author":"Venkadakrishnan","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.eururo.2025.06.013_b0245","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1158\/2159-8290.CD-18-0469","article-title":"Aurora A kinase inhibition is synthetic lethal with loss of the RB1 tumor suppressor gene","volume":"9","author":"Gong","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.eururo.2025.06.013_b0250","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1158\/2159-8290.CD-11-0130","article-title":"Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets","volume":"1","author":"Beltran","year":"2011","journal-title":"Cancer Discov"},{"key":"10.1016\/j.eururo.2025.06.013_b0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1593\/neo.121550","article-title":"Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer","volume":"15","author":"Mosquera","year":"2013","journal-title":"Neoplasia"},{"key":"10.1016\/j.eururo.2025.06.013_b0260","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/1078-0432.CCR-18-1912","article-title":"A phase II trial of the Aurora kinase A inhibitor alisertib for patients with castration-resistant and neuroendocrine prostate cancer: efficacy and biomarkers","volume":"25","author":"Beltran","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2025.06.013_b0265","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41392-024-01908-y","article-title":"CDC7 inhibition impairs neuroendocrine transformation in lung and prostate tumors through MYC degradation","volume":"9","author":"Quintanal-Villalonga","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.eururo.2025.06.013_b0270","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1158\/2767-9764.CRC-22-0277","article-title":"Safety, tolerability, and pharmacokinetics of TAK-931, a cell division cycle 7 inhibitor, in patients with advanced solid tumors: a phase I first-in-human study","volume":"2","author":"Kuboki","year":"2022","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.eururo.2025.06.013_b0275","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1172\/JCI122622","article-title":"Inhibiting Wee1 and ATR kinases produces tumor-selective synthetic lethality and suppresses metastasis","volume":"129","author":"Bukhari","year":"2019","journal-title":"J Clin Invest"},{"issue":"16_suppl","key":"10.1016\/j.eururo.2025.06.013_b0280","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1200\/JCO.2024.42.16_suppl.5061","article-title":"Phase 1 trial of mevrometostat (PF-06821497), a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in castration-resistant prostate cancer (CRPC)","volume":"42","author":"Schweizer","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"10.1016\/j.eururo.2025.06.013_b0285","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS282","article-title":"A multi-center, open-label, randomized dose expansion study of PF-06821497, a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"41","author":"Calvo","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"10.1016\/j.eururo.2025.06.013_b0290","article-title":"Mevrometostat (PF-06821497), an EZH2 inhibitor, in combination with enzalutamide in patients with mCRPC: a randomized dose-expansion study","volume":"43","author":"Schweizer","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.06.013_b0295","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1158\/1078-0432.CCR-22-2526","article-title":"Phase I study of niraparib in combination with radium-223 for the treatment of metastatic castrate-resistant prostate cancer","volume":"29","author":"Quinn","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2025.06.013_b0300","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.06.013_b0305","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","article-title":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial","volume":"24","author":"Saad","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.06.013_b0310","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41591-023-02704-x","article-title":"First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial","volume":"30","author":"Fizazi","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.eururo.2025.06.013_b0315","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.annonc.2023.06.009","article-title":"Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial","volume":"34","author":"Chi","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2025.06.013_b0320","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S1470-2045(18)30786-1","article-title":"Exploring and comparing adverse events between PARP inhibitors","volume":"20","author":"LaFargue","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.06.013_b0325","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","article-title":"Radiopharmaceutical therapy in cancer: clinical advances and challenges","volume":"19","author":"Sgouros","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.eururo.2025.06.013_b0330","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2025.06.013_b0335","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","article-title":"[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial","volume":"25","author":"Emmett","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.06.013_b0340","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1470-2045(23)00638-1","article-title":"Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study","volume":"25","author":"Sathekge","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.06.013_b0345","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00259-019-04612-0","article-title":"225Ac-PSMA-617\/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience","volume":"47","author":"Khreish","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2025.06.013_b0350","doi-asserted-by":"crossref","first-page":"62","DOI":"10.2967\/jnumed.119.229229","article-title":"Predictors of overall and disease-free survival in metastatic castration-resistant prostate cancer patients receiving 225Ac-PSMA-617 radioligand therapy","volume":"61","author":"Sathekge","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2025.06.013_b0355","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/pros.23765","article-title":"Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer","volume":"79","author":"Petrylak","year":"2019","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2025.06.013_b0360","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/pros.23922","article-title":"PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and\/or enzalutamide: efficacy and safety in open-label single-arm phase 2 study","volume":"80","author":"Petrylak","year":"2020","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2025.06.013_b0365","doi-asserted-by":"crossref","first-page":"530.e15","DOI":"10.1016\/j.urolonc.2016.07.005","article-title":"Phase 1\/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer","volume":"34","author":"Milowsky","year":"2016","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2025.06.013_b0370","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.annonc.2021.03.005","article-title":"Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2025.06.013_b0375","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1470-2045(18)30859-3","article-title":"Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1\u20132 trial","volume":"20","author":"de Bono","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.06.013_b0380","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1200\/JCO.19.00646","article-title":"Phase I study of DSTP3086S, an antibody-drug conjugate targeting six-transmembrane epithelial antigen of prostate 1, in metastatic castration-resistant prostate cancer","volume":"37","author":"Danila","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.06.013_b0385","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1158\/2159-8290.CD-23-0964","article-title":"Xaluritamig, a STEAP1 \u00d7 CD3 XmAb 2+1 immune therapy for metastatic castration-resistant prostate cancer: results from dose exploration in a first-in-human study","volume":"14","author":"Kelly","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.eururo.2025.06.013_b0390","doi-asserted-by":"crossref","first-page":"6207","DOI":"10.1158\/0008-5472.CAN-21-3360","article-title":"HER3 is an actionable target in advanced prostate cancer","volume":"81","author":"Gil","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2025.06.013_b0395","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1038\/s41591-023-02284-w","article-title":"Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial","volume":"29","author":"Shenderov","year":"2023","journal-title":"Nat Med"},{"issue":"Suppl 2","key":"10.1016\/j.eururo.2025.06.013_b0400","doi-asserted-by":"crossref","first-page":"S996","DOI":"10.1016\/j.annonc.2024.08.1735","article-title":"TAMARACK: randomized phase II trial of the B7-H3 targeting antibody drug conjugate (ADC) vobramitamab duocarmazine (vobra duo) in metastatic castration-resistant prostate cancer (mCRPC)","volume":"35","author":"de Bono","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2025.06.013_b0405","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.06.013_b0410","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.06.013_b0415","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/vco.12469","article-title":"Nectin-4 and p63 immunohistochemical expression in canine prostate tumourigenesis","volume":"17","author":"Della Salda","year":"2019","journal-title":"Vet Comp Oncol"},{"key":"10.1016\/j.eururo.2025.06.013_b0420","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1200\/JCO.19.01638","article-title":"Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study","volume":"38","author":"Antonarakis","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.06.013_b0425","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.eururo.2022.08.005","article-title":"Pembrolizumab plus olaparib in patients with metastatic castration-resistant prostate cancer: long-term results from the phase 1b\/2 KEYNOTE-365 cohort A study","volume":"83","author":"Yu","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.06.013_b0430","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1200\/JCO.23.00233","article-title":"Pembrolizumab plus olaparib for patients with previously treated and biomarker-unselected metastatic castration-resistant prostate cancer: the randomized, open-label, phase III KEYLYNK-010 trial","volume":"41","author":"Antonarakis","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.06.013_b0435","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S1470-2045(22)00278-9","article-title":"Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021)","volume":"23","author":"Agarwal","year":"2022","journal-title":"Lancet Oncol"},{"issue":"6_suppl","key":"10.1016\/j.eururo.2025.06.013_b0440","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1200\/JCO.2023.41.6_suppl.22","article-title":"Nivolumab plus ipilimumab for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC): additional results from the randomized phase 2 CheckMate 650 trial","volume":"41","author":"Sharma","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.06.013_b0445","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1158\/1078-0432.CCR-20-4790","article-title":"Radium-223 treatment increases immune checkpoint expression in extracellular vesicles from the metastatic prostate cancer bone microenvironment","volume":"27","author":"Vardaki","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"6_suppl","key":"10.1016\/j.eururo.2025.06.013_b0450","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1200\/JCO.2021.39.6_suppl.98","article-title":"Randomized phase II study evaluating the addition of pembrolizumab to radium-223 in metastatic castration-resistant prostate cancer","volume":"39","author":"Choudhury","year":"2021","journal-title":"J Clin Oncol"},{"issue":"Suppl 5","key":"10.1016\/j.eururo.2025.06.013_b0455","doi-asserted-by":"crossref","first-page":"S626","DOI":"10.1016\/j.annonc.2021.08.1090","article-title":"577O PRINCE: Interim analysis of the phase Ib study of 177Lu-PSMA-617 in combination with pembrolizumab for metastatic castration-resistant prostate cancer (mCRPC)","volume":"32","author":"Sandhu","year":"2021","journal-title":"Ann Oncol"},{"issue":"6_suppl","key":"10.1016\/j.eururo.2025.06.013_b0460","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS271","article-title":"Evolution: phase II study of radionuclide 177Lu-PSMA-617 therapy versus 177Lu-PSMA-617 in combination with ipilimumab and nivolumab for men with metastatic castration-resistant prostate cancer (mCRPC; ANZUP 2001)","volume":"41","author":"Sandhu","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.06.013_b0465","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-21-0327","article-title":"FDA approval summary: pembrolizumab for the treatment of tumor mutational burden-high solid tumors","volume":"27","author":"Marcus","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2025.06.013_b0470","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.06.013_b0475","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1200\/PO.19.00399","article-title":"CDK12-altered prostate cancer: clinical features and therapeutic outcomes to standard systemic therapies, poly (ADP-ribose) polymerase inhibitors, and PD-1 inhibitors","volume":"4","author":"Antonarakis","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.eururo.2025.06.013_b0480","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1200\/PO.19.00383","article-title":"CDK12-mutated prostate cancer: clinical outcomes with standard therapies and immune checkpoint blockade","volume":"4","author":"Schweizer","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.eururo.2025.06.013_b0485","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1158\/2159-8290.CD-24-0052","article-title":"Novel WRN helicase inhibitors selectively target microsatellite-unstable cancer cells","volume":"14","author":"Picco","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.eururo.2025.06.013_b0490","doi-asserted-by":"crossref","first-page":"4871","DOI":"10.1158\/1078-0432.CCR-22-0612","article-title":"Phase Ia\/b, open-label, multicenter study of AZD4635 (an adenosine A2A receptor antagonist) as monotherapy or combined with durvalumab, in patients with solid tumors","volume":"28","author":"Lim","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2025.06.013_b0495","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1158\/1078-0432.CCR-23-2978","article-title":"A phase I study of acapatamab, a half-life extended, PSMA-targeting bispecific T-cell engager for metastatic castration-resistant prostate cancer","volume":"30","author":"Dorff","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"6_suppl","key":"10.1016\/j.eururo.2025.06.013_b0500","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS197","article-title":"Phase 1b study of tarlatamab, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in de novo or treatment emergent neuroendocrine prostate cancer (NEPC)","volume":"40","author":"Aggarwal","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.06.013_b0505","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41698-021-00214-y","article-title":"A phase I\/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors","volume":"5","author":"Mansfield","year":"2021","journal-title":"NPJ Precis Oncol"},{"issue":"6_suppl","key":"10.1016\/j.eururo.2025.06.013_b0510","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1200\/JCO.2023.41.6_suppl.154","article-title":"Preliminary results from a phase 1\/2 study of co-stimulatory bispecific PSMAxCD28 antibody REGN5678 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","volume":"41","author":"Stein","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"10.1016\/j.eururo.2025.06.013_b0515","doi-asserted-by":"crossref","first-page":"094","DOI":"10.1200\/JCO.2022.40.6_suppl.094","article-title":"Safety and early efficacy results from a phase 1, multicenter trial of PSMA-targeted armored CAR T cells in patients with advanced mCRPC","volume":"40","author":"McKean","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.06.013_b0520","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41586-020-2403-9","article-title":"Senolytic CAR T cells reverse senescence-associated pathologies","volume":"583","author":"Amor","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.eururo.2025.06.013_b0525","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/s41586-023-06696-z","article-title":"Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance","volume":"623","author":"Guo","year":"2023","journal-title":"Nature"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825003574?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825003574?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T22:28:07Z","timestamp":1760048887000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283825003574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":106,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0302283825003574"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2025.06.013","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel Therapeutic Strategies for Metastatic Prostate Cancer Care","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2025.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}